Detection of drug resistance-associated and background mutations in human immunodeficiency virus type 1 CRF01-AE protease and reverse transcriptase derived from drug treatment-naive patients residing in central Thailand

AIDS Research and Human Retroviruses

Volumn 25, Issue 6, 2009, Pages 625-631

  Auwanit, Wattana ^a   Isarangkura Na Ayuthaya, Panasda ^a   Kasornpikul, Dao ^a   Ikuta, Kazuyoshi ^b,c   Sawanpanyalert, Pathom ^a   Kameoka, Masanori ^a,b,c  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b Thailand Japan Research Collaboration Center on Emerging and Re emerging Infections RCC ERI   (Thailand)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 CRF01 AE; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; THAILAND; VIRUS DETECTION; VIRUS MUTATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DNA SEQUENCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MISSENSE MUTATION; MOLECULAR GENETICS; VIROLOGY;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA; THAILAND;

EID: 67651154279     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0298     Document Type: Article

References (15)

1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, and Chodakewitz JA: Treatment with in-dinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
2. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA, and Fischl MA: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.
3. Sutthent R, Arworn D, Kaoriangudom S, Chokphaibulkit K, Chaisilwatana P, Wirachsilp P, Thiamchai V, Sirapraphasiri T, and Tanprasertsuk S: HIV-1 drug resistance in Thailand: Before and after National Access to Antiretroviral Program. J Clin Virol 2005;34:272-276.
4. Conway B, Wainberg MA, Hall D, Harris M, Reiss P, Cooper D, Vella S, Curry R, Robinson P, Lange JMA, and Montaner JSG: Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 2001;15:1269-1274.
5. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled, M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, and Mellors J: The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000;5:41-48.
6. Ross L, Johnson M, DeMasi R, Liao Q, Graham N, Shaefer M, and St Clair M: Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremia. AIDS 2000;14:813-819.
7. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recom-binants in 2004. AIDS 2006;20:W13-W23.
8. McCutchan FE: Global epidemiology of HIV. J Med Virol 2006;78:S7-S12.
9. Johnson VA, Brun-Vezinet F, Clotet B, Gü nthard HF, Kuritzkes DR, Pillay D, Schapiro JM, and Richman DD: Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008;16:62-68.
10. Shafer RW, and Schapiro JM: HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev 2008;10:67-84.
11. Sukasem C, Churdboonchart V, Sirisidthi K, Riengrojpitak S, Chasombat S, Watitpun C, Piroj W, Tiensuwan M, and Chantratita W: Genotypic resistance mutations in treatment-naive and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: Implications for further epidemiologic surveillance. Jpn J Infect Dis 2007;60:284-289.
12. Sukasem C, Churdboonchart V, Sukeepaisarncharoen W, Piroj W, Inwisai T, Tiensuwan M, and Chantratita W: Gen-otypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: Impact of polymorphism on resistance to therapy. Int J Antimicrob Agents 2008;31:277-281.
13. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Lie-geois F, Toure-Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, Reynes J, and Delaporte E: Genetic iversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000;38:3919-3925.
14. Myint L, Ariyoshi K, Yan H, Frater AJ, Auwanit W, Pathipvanith P, Yamada K, Matsuda M, Chiba T, Fujita K, McClure M, Weber JN, and Sugiura W: Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01-AE (subtype E) human immunodeficiency virus type 1. Antimicrob. Agents Chemother 2002;46:3861-3868.
15. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, and Gingeras TR: Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996;2:753-759.